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Abstract
Familial hypercholesterolemia (FH) is the genetic disease which characterized 
by an increase of level total cholesterol and low density lipoproteins since child-
hood. The aim of the study was to assess arterial stiffness in children with hetero-
zygous FH by measuring the pulse wave velocity (PWV) in the aorta. The study 
involved 118 children, 60 healthy children in the control group and 58 children with 
heterozygous FH in the main group. Both groups were divided into 3 age subgroups: 
5–7 years old, 8–12 years old and 13–17 years old. The diagnosis of FH was made 
using British criteria by Simon Broome. The lipid profile was determined for all 
children, blood pressure was monitored daily with an estimate of the minimum, 
mean and maximum PWV (PWVmin, mean PWV, PWVmax) in aorta using oscil-
lometric method. Correlation analysis in patients with FH revealed direct correla-
tion between PWVmin, mean PWV and PWVmax with total cholesterol (r = 0.46, 
r = 0.46 and r = 0.464, respectively, p < 0.001). The study demonstrates an increase 
in the PWV in the aorta in children with FH compared with healthy peers from 
8–12 years of age and a progression of arterial stiffness most significant in the group 
of 13–17 years.
Keywords: familial hypercholesterolemia, arterial stiffness, pulse wave velocity, 
children
1. Introduction
Familial hypercholesterolemia (FH) is a monogenic disease with a predomi-
nantly autosomal dominant mode of inheritance, accompanied by a significant 
increase of the low-density lipoprotein cholesterol (LDL-C) level in the blood [1]. 
Patients with FH have a high risk of early development of atherosclerosis [2, 3]. The 
incidence of FH in the general population is estimated at about 1 per 200 persons 
[3], in addition, the evidence exist that in patients with established coronary heart 
disease, the prevalence of potential FH is up to 8.3% in men and 11.1% in women 
[4]. However, despite this, there is a low level of diagnosis and treatment [5, 6]. In 
this regard, registers of patients with FH have recently been developed for assessing 
the level of diagnosis, treatment and improvement in results of therapy [7, 8]. In 
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more than 90% of cases, FH is caused by mutations in the gene encoding the LDL 
receptor, which reduce the cellular uptake of LDL and, therefore, significantly 
increase their plasma level [9]. Mutations in other genes leading to the same pheno-
type have also been identified: associated with apolipoprotein B, which affect the 
LDL-binding domain of apolipoprotein B as the most important apolipoprotein for 
uptake of LDL particles, and mutations in proprotein convertase subtilisin/kexin 
type 9 (PCSK9) [10, 11].
It is known that high plasma cholesterol level is a risk factor for the development 
of cardiovascular diseases [12] and may be the cause of early vascular damage. 
Currently, there are methods that allow registering pathological changes in blood 
vessels at preclinical stage. The detection of early changes in the walls of arteries by 
non-invasive methods, such as ultrasound duplex scanning, assessment of central 
aortic pressure and pulse wave velocity, has opened up new perspectives, helping to 
identify high-risk patients [13–17].
Several studies have shown that hypercholesterolemia can cause the loss of 
elasticity and increased stiffness of arterial vessels, leading to an increase in the 
pulse wave velocity due to its rapid spreading in stiff arteries [18, 19]. Arterial 
stiffness is considered to be a significant predictor of overall and cardiovascular 
mortality in patients with arterial hypertension [20–23], in patients with end-
stage renal failure [24, 25] and in the elderly patients [26]. In addition, it was 
noted that arterial stiffness is closely related to structural changes in the artery 
such as thickening of the intima-media complex [27]. Changes in the elastic 
properties of arteries may indicate a functional disorder long before the appear-
ance of clinical symptoms. One of the indicators for assessing the stiffness of the 
arteries is the pulse wave velocity (PWV) measurement in aorta. It is the mea-
surement of the speed of pulse pressure propagation along a segment of the arte-
rial vessels [28]. It should be noted that the measurement of the arterial stiffness 
is quite widespread among adult patients [29, 30], while in pediatrics, despite its 
non-invasiveness and high informativeness, it is used much less frequently. This 
is probably due to the complexity of standardization, time costs and the need for 
additional equipment.
2. The aim of this study
The aim of this study is to assess arterial stiffness in children with hetero-
zygous familial hypercholesterolemia by measuring the pulse wave velocity in 
the aorta
3. Materials and methods
The study involved 118 children. The control group consisted of 60 healthy 
children and 58 children with heterozygous familial hypercholesterolemia formed 
the main group (Table 1). The diagnosis of FHC was established in accordance with 
the British Simon Broome criteria [31]. The study included children with FH who 
were not taking statins. 15 patients from the main group underwent genetic testing 
in the Health in Code laboratory (Spain) for the detection of a monogenic mutation 
responsible for the development of familial hypercholesterolemia, and a positive 
DNA test was obtained. Exclusion criteria: secondary dyslipidemia, arterial hyper-
tension, obesity. Written informed consent was obtained from all the participants 
of the study.
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Total cholesterol, triglycerides, LDL, and high-density lipoprotein cholesterol 
(HDL) were measured using commercial kits (Beckman Coulter, USA) on an 
automatic biochemical analyzer (Au5800 Beckman Coulter, USA).
The clinical examination included a careful life history and family history 
taking, physical examination, and body mass index (BMI) assessment. All children 
underwent 24-hour blood pressure monitoring with an assessment of the pulse 
wave velocity in the aorta using the oscillometric method of the BPLab Vasotens 
system (Petr Telegin Ltd., Russia).
In the BPLab program for determining PWV in aorta the following ratio is 
used: PWVaorta = K × (2 × L) /RWTT, where PWVaorta is PWV in the aorta; K is 
the scale factor for standardizing the obtained value of the PWV; L is the length 
of the aortic trunk (in BPLab software, the distance from the upper edge of the 
sternum to the pubic bone is taken as the length of the aorta); RWTT (reflected 
wave transit time) [32].
4. Statistical analysis
Statistical analysis was carried out using the IBM SPSS Statistics v.23 software 
(developed by IBM Corporation, USA). The results were subjected to statisti-
cal processing using nonparametric methods in connection with the established 
absence of a normal distribution of quantitative indicators (testing for normal 
distribution was carried out using the Shapiro–Wilk test). Quantitative data were 
described using the values of the median (Me) and the lower and upper quartiles 
[Q1-Q3]. Comparison of quantitative indicators between two groups was carried 
out using the Mann–Whitney test, between the three groups using the Kruskal-
Wallis test with an a posteriori Dunn test. Correlation analysis was carried out 
using the Spearman’s rank correlation coefficient; the assessment of the tightness of 
correlation was carried out using the Chaddock scale. Differences in indicators and 
identified relationships were considered statistically significant at p < 0.05.
Control group, n = 60 Main group, n = 58
Age, years (М ± σ) 11,53 ± 4,2 10,92 ± 4,1
Gender, m/f 40/20 37/21
Smoking, n/% 0(0) 0(0)
Obesity, n/% 0(0) 0(0)
Arterial hypertension, n/% 0(0) 0(0)
Cutaneous xanthomas 0(0) 0(0)
Corneal arch 0(0) 0(0)
Thickening of the Achilles tendon 0(0) 0(0)
TC, mmol/l (М ± σ) 3,5 ± 1,2 7,8 ± 2,3
LDL, mmol/l (М ± σ) 1,6 ± 0,8 6,1 ± 1,2
HDL, mmol/l (М ± σ) 0,9 ± 0,1 1,1 ± 0,3
TG, mmol/l (М ± σ) 0,8 ± 0.4 1,2 ± 0,3
Abbreviations: TC - total cholesterol; LDL - low density lipoprotein; HDL - high density lipoprotein;  
TG - triglycerides.
Table 1. 




Analysis of the values of the minimum PWV (PWVmin), mean PWV 
(PWVmean) and maximum PWV (PWVmax) obtained during 24-hour blood 
pressure monitoring revealed statistically significant differences between the main 
and control groups (p < 0.001) (Figure 1). The presence of FHC was accompanied 
by a significant increase in PWV - minimum, mean and maximum values.
Taking into account the results obtained, we analyzed the degree of change in 
PWV depending on the age of children. For the analysis, both groups were divided 
into 3 age subgroups: from 5 to 7 years old, from 8 to 12 years old, from 13 to 
17 years old (Table 2).
In accordance with the results obtained, in the younger age subgroup (5–7 years 
old), there were no statistically significant differences in PWV between the chil-
dren of the main and control groups. In children aged 8–12 years, there was no 
statistically significant difference in the values of PWV min and mean PWV. While 
PWVmax was characterized by statistically significantly higher values in the main 
group (5.1 [4.7–5.8] m/s) relative to the control (4.6 [4.45–5.05] m/s) (p = 0.041). 
The most pronounced changes were found in the group of children with FHC at the 
age of 13–17 years. In this group were revealed statistically significant differences in 
the minimum, mean and maximum pulse wave velocity.
Taking into account the peculiarities of physical parameters and age periodiza-
tion, we have analyzed the dynamics of changes in PWV depending on the age of 
children. In children of the control group, PWVmin in children 8–12 year old was 
statistically significantly higher than in children 5–7 year old (3.6 [3.2–4.1] m/s and 
3.0 [2.8–3.1] m/s, respectively, p = 0.049). When comparing PWVmin in groups of 
8–12 years old children and 13–17 years old children, no statistically significant dif-
ference was found (3.6 [3.2–4.1] m/s and 3.9 [3.5–4.1] m/s, respectively, p = 0.052). 
A similar dynamics of growth was observed for the mean pulse wave velocity in 
healthy children when compared in age subgroups 8–12 years old and 5–7 years old 
(4.3 [3.7–5.1] m/s and 3.8 [3.7–3.9] m/s, respectively, p = 0.026) and 8–12 years old 
and 13–17 years old (4.3 [3.7–5.1] m/s and 4.5 [4.2–4, 9] m/s, respectively, p = 0.114). 
Figure 1. 
Comparison of the values of the pulse wave velocity in the main and control groups. Note: *** - p < 0.001.
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The analysis of PWVmax showed that these indicators in the group of 5–7 years 
old and 8–12 years old children did not significantly differ from each other (4.5 
[4.3–4.8] m/s and 4.6 [4.45–5.05] m/s, p = 0.145), while in children 13–17 years old it 
was significantly higher in comparison with 8–12 years old children (5.4 [5.05–5.6] 
m/s and 4.6 [4, 45–5.05] m/s, respectively, p = 0.022). It should be noted that there 
is a statistically significant difference in the values of PWVmin, mean PWV and 
PWVmax in children 13–17 years old relatively to 5–7 years old (Table 3).
The study of PWV in children of the main group revealed a statistically signifi-
cant difference in the increase in PWVmin, mean PWV and PWVmax indicators 
when compared in all main groups (Table 4).
Parameter
m/s
Control group Main group p
Me Q1-Q3 Me Q1-Q3
5–7 years (n = 15) 5–7 years (n = 16)
PWVmin 3,0 2,8-3,1 3,05 2,6-3,3 0,19
PWVmean 3,8 3,7-3,9 4,1 3,8-4,1 0,19
PWVmax 4,5 4,3-4,8 4,8 4,1-5,3 0,095
8–12 years (n = 22) 8–12 years (n = 21)
PWVmin 3,6 3,2-4,1 3,5 3,3-3,9 0,052
PWVmean 4,3 3,7-5,1 4,6 4,0-5,0 0,05
PWVmax 4,6 4,45-5,05 5,1 4,7-5,8 0,041
13–17 years (n = 21) 13–17 years (n = 23)
PWVmin 3,9 3,5-4,1 4,7 4,1-5,1 0,009
PWVmean 4,5 4,2-4,9 5,5 4,8-6,4 0,009
PWVmax 5,4 5,05-5,6 6,2 5,7-7,55 0,007
Table 2. 
Comparison of the values  of the pulse wave velocity depending on the age of the children.
Parameter, m/s 5–7 years 8–12 years 13-17 years Р1–2 Р2–3 Р1–3
PWVmin 3,0 [2,8-3,1] 3,6 [3,2-4,1] 3,9 [3,5-4,1] 0,049 0,052 0,043
PWVmean 3,8 [3,7-3,9] 4,3 [3,7-5,1] 4,5[4,2-4,9] 0,026 0,114 0,047
PWVmax 4,5 [4,3-4,8] 4,6 [4,45-5,05] 5,4 [5,05-5,6] 0,145 0,022 0,018
Note: p is the level of significance of the differences.
Table 3. 
Indicators of the pulse wave velocity of children of the control group.
Parameter, m/s 5–7 years 8–12 years 13–17 years Р1–2 Р2–3 Р1–3
PWVmin 3,05[2,6-3,3] 3,5 [3,3-3,9] 4,7 [4,1-5,1] 0,001 0,004 0,008
PWVmean 4,1 [3,8-4,1] 4,6 [4,0-5,0] 5,5[4,8-6,4] 0,001 0,016 0,004
PWVmax 4,8 [4,1-5,3] 5,1 [4,7-5,8] 6,2 [5,7-7,55] 0,028 0,021 0,018
Note: p is the level of significance of the differences.
Table 4. 
Indicators of the pulse wave velocity of children of the main group.
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At the same time, a more significant dynamics of increase in PWV was observed 
in children with FH compared with the control group in the age range of 13–17 years 
(Figure 2). It should be noted that the dynamics of the increase in indicators in the 
control group was less than in children with FH (Figure 3).
Taking into account the presence of dyslipidemia in patients with FH in the form 
of severe hypercholesterolemia, we performed a correlation analysis of the relation-
ship between PWV values and lipid metabolism indicators. In the main group, 
statistically significant direct correlations were established between PWVmin, 
mean PWV and PWVmax with total cholesterol level (rxy = 0.46 [95% CI: 0.227–
0.644], rxy = 0.46 [95% CI: 0.229–0.642] and rxy = 0.464 [95% CI: 0.234–0.645], 
 respectively, p < 0.001 in all cases).
Figure 2. 
Indicators of the pulse wave velocity of the main and control groups, depending on the age of the children. Note: 
PWVmin - minimum pulse wave velocity, PWVmean - mean pulse wave velocity, PWVmax - maximum pulse 
wave velocity.
Figure 3. 
Dynamics of the increase in the mean pulse wave velocity in the main and control groups, depending on the age 
of the children. Note: * - p = 0.009.
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6. Discussion
In the presented study, the condition of the arterial wall was assessed by measur-
ing the pulse wave velocity in the aorta in children with FH and healthy children of 
the same age. The study design differs from previous studies of PWV in the pediat-
ric population presented in the literature [33–36] in distribution of participants into 
age subgroups. In our opinion, such an analysis of the PWV values increases the 
correctness and statistical significance of the obtained results.
We found that the PWV values of children of the main group at the age of 
5–7 years do not differ from those of the control group. In the 8–12-year-old 
subgroup in patients with FH, only the maximum PWV indicators were statisti-
cally significantly higher than in the comparison group. The identified deviations 
probably reflect the initial changes in the stiffness of the vascular wall in children 
of the main group. The most pronounced differences in the studied parameters 
were observed in children with FH in the age subgroup of 13–17 years old and were 
characterized by a statistically significant increase in PWVmin, mean PWV and 
PWmax relatively to the control group.
In our study, we also analyzed the dynamics of PWV growth depending on age. 
It was shown that PWV values increase with the age of the child both in familial 
hypercholesterolemia and in healthy children. This indicates that the studied 
indicators cannot be the same for all children and it is necessary to use age reference 
values in pediatrics. In addition, the increase in all three values of PWV was most 
pronounced in the group of 13–17 year old patients with FH, it allows us to suggest 
that they have a more pronounced change of properties of the vascular wall already 
at preclinical stages than in individuals with normal blood lipid profile.
A number of studies have revealed an increased PWV in children with hyper-
tension [37], increased body mass index [38, 39]. In the present study, special 
attention was paid to patients with FH without risk factors such as smoking, 
obesity, and high blood pressure. Thus, the authors were able to assess the effect of 
hypercholesterolemia on the change in PWV precisely. The established correlation 
between total cholesterol level and PWV values allows us to regard an increase in 
total cholesterol level as a leading factor in forming the arterial stiffness in children 
with FH. In addition, the registration of the initial changes in PWV in the group 
with FH from 8–12 years old with further progression of the process in the absence 
of such changes in children 5–7 years old indicates a possible cumulative effect of 
cholesterol and its effect on the artery wall condition. This is consistent with large 
randomized studies showing that the effect of LDL on the development of athero-
sclerotic vascular disease is determined not only by the absolute level of LDL, but 
also by its cumulative effect on target organs [2, 40, 41].
7. Conclusion
Thus, the relationship between cholesterol level, age, and arterial stiffness indi-
cators in familial hypercholesterolemia makes it possible to recommend the study of 
pulse wave velocity as a possible additional method for studying the cardiovascular 
risk in children with familial hypercholesterolemia and assessing the progression of 
the disease
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